Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma

Bone Marrow Transplantation
Dg Maloney

Abstract

Allogeneic hematopoietic SCT following myeloablative conditioning is associated with a high nonrelapse mortality and usually reserved for young, medically fit patients. The use of allogeneic stem cells is associated with a less risk of relapse, but is also associated with the risk of GVHD. The increased antitumor activity is due to graft-vs-tumor immune responses. The newer use of nonmyeloablative or reduced-intensity conditioning has decreased the toxicity of this approach and allows the treatment of older patients or those with medical comorbidities that preclude the use of a myeloablative regimen. A nonmyeloablative regimen using fludarabine and 2 Gy TBI was developed in Seattle that reliably allows allogeneic engraftment from either matched related or unrelated donor stem cell sources. Here we describe our results using this regimen in multicenter studies for the treatment of aggressive non-Hodgkin's lymphoma (NHL) and mantle cell NHL.

Citations

Aug 4, 2012·Bone Marrow Transplantation·S O AhmedM Aljurf
Dec 21, 2010·Current Opinion in Oncology·Nicolas Mounier, Christian Gisselbrecht
Nov 19, 2010·Expert Review of Hematology·Michael HudecekStanley R Riddell
Mar 11, 2010·Expert Review of Anticancer Therapy·Niels MurawskiMichael Pfreundschuh
Apr 15, 2009·Expert Opinion on Pharmacotherapy·Mark PrichardJohn J Densmore
Apr 20, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Gordon CookUNKNOWN Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT)
Sep 26, 2012·Blood·Ulrike BacherUNKNOWN Lymphoma Working Committee of the CIBMTR

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

© 2022 Meta ULC. All rights reserved